Evaluation of the Clinical Efficacy of Liquid Resuscitation Combined with Ulinastatin in Patients with Sepsis

We attempts to exam the clinical efficacy of fluid resuscitation combined with ulinastatin in treatment of patients with sepsis and to analyze the effects of the combination on acute physiology and chronic health evaluation II score, sequential organ failure assessment score, oxygenation index and inflammatory factors. We chose 60 patients with sepsis from July 2020 to July 2021 in the intensive care unit ward of our hospital as the study cohort. Divided them into two groups, one is control group (n=30) and the other is observation group (n=30) randomly. Patients in control group were offered basic treatments such as antibiotics, nutritional support and blood pressure drugs, and were given fluid resuscitation at the same time. After the observation group was treated the same as the control group add ulinastatin injection. Contrast the changes in acute physiology and chronic health evaluation II score, sequential organ failure assessment score, incidence of disseminated intravascular coagulation and multiple organ dysfunction syndrome, changes in oxygenation index, serum creatinine, total bilirubin and inflammatory factors among both groups after treatment, then contrast the mortality and clinical effectiveness of both groups as well. After treatment, observation groups acute physiology and chronic health evaluation II score, sequential organ failure assessment score, organ injury, serum creatinine, total bilirubin, inflammation indicators (C-reactive protein, procalcitonin, interleukin-6) were remarkably lowered (p<0.05). Contrast the clinical effective rate of both groups, observation group efficiency was higher (p<0.05), but disseminated intravascular coagulation, multiple organ dysfunction syndrome and mortality incidence in observation group was lower (p<0.05), with statistical differences. Liquid resuscitation combined with ulinastatin has important clinical significance in the treatment of sepsis, improving the effective rate of clinical treatment, reducing the incidence of disseminated intravascular coagulation, multiple organ dysfunction syndrome and mortality in the group, improving inflammatory factors, organ dysfunction parameters and other indicators, which are worth of clinical promotion.